Vim Cancer Research Results

Vim, Vimentin: Click to Expand ⟱
Source:
Type:
Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.

In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment.
The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression.

High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers.
Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence.
As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival.
- vimentin up-regulation is often used as a marker of EMT in cancer



NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
2433- 2DG,    Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2 /mTORC1-induced autophagy
- in-vitro, Arthritis, NA - in-vivo, NA, NA
Vim↓, HK2↓,
1097- AG,    Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin
- in-vitro, Nor, HMrSV5 - in-vivo, NA, NA
*EMT↓, *E-cadherin↑, *α-SMA↓, *Vim↓, *β-catenin/ZEB1↓, *Smad7↑,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1098- BA,    Baicalein inhibits fibronectin-induced epithelial–mesenchymal transition by decreasing activation and upregulation of calpain-2
- in-vitro, Nor, MCF10 - in-vivo, NA, NA
*TumCMig↓, *F-actin↓, *E-cadherin↑, *ZO-1↑, *N-cadherin↓, *Vim↓, *Snail↓, *cal2↓, *Ca+2↝,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
2047- Buty,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24/HTB-9 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
1103- CBD,    Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway
- vitro+vivo, NA, NA
Apoptosis↑, TumCP↓, TumCMig↓, TumMeta↓, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, Hif1a↓, Wnt/(β-catenin)↓, AXIN1↑, TumVol↓, TumW↓,
692- EGCG,    EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement
- Review, NA, NA
ROS↑, Apoptosis↑, DNAdam↑, CTR1↑, JWA↑, β-catenin/ZEB1↓, P53↑, Vim↓, VEGF↓, p‑Akt↓, Hif1a↓, COX2↓, ERK↓, NF-kB↓, Akt↓, Bcl-xL↓, miR-210↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,
800- GAR,    Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
EMT↓, MET↑, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↑, miR-200c↑, Let-7↑, p‑β-catenin/ZEB1↓, NF-kB↓,
2880- HNK,    Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vivo, NA, NA
tumCV↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, TumMeta↓, p‑eIF2α↑,
1100- LT,    Luteolin, a flavonoid, as an anticancer agent: A review
- Review, NA, NA
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, ROS↑, ER Stress↑, mtDam↑, p‑eIF2α↝, p‑PERK↝, p‑CHOP↝, p‑ATF4↝, cl‑Casp12↝,
2905- LT,    Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions
- in-vivo, NA, HMrSV5
*ROS↓, *p‑Akt↓, *Vim↓, *E-cadherin↑, *PI3K↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
53- QC,    Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer
- in-vitro, BC, MDA-MB-231 - NA, NA, MDA-MB-468
E-cadherin↑, Vim↓, cycD1/CCND1↓, cMyc↓, EMT↓, TumCG↓, TumCMig↓, β-catenin/ZEB1↓, ChemoSen↑,
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, eff↑, CSCs↓, TumCG↓, tumCV↓,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, eff↑, HK2↓, ROS↑, MMP↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
1217- VitC,    High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition
- in-vitro, BC, Bcap37 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, Vim↓, EMT↓,

Showing Research Papers: 1 to 22 of 22

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 22

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

frataxin↑, 1,   NRF2↑, 1,   PARK2↑, 1,   ROS↓, 1,   ROS↑, 7,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 4,   mtDam↑, 1,   OCR↓, 1,   PINK1↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   cMyc↓, 4,   ECAR↓, 1,   Glycolysis↓, 1,   HK2↓, 2,   lactateProd↓, 1,   LDHA↓, 1,   NADPH↓, 1,   PDK1↓, 1,   p‑PDK1↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 1,   SIRT1↓, 2,   SIRT2↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 2,   Apoptosis↑, 3,   BAX↑, 3,   Bcl-2↓, 4,   Bcl-xL↓, 4,   Casp↑, 1,   cl‑Casp12↝, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp9↑, 2,   Cyt‑c↑, 1,   IAP1↓, 1,   JWA↑, 1,   Mcl-1↓, 1,   p27↑, 1,   survivin↓, 3,   Telomerase↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   HATs↑, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

p‑CHOP↝, 1,   p‑eIF2α↑, 2,   p‑eIF2α↝, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   PERK↑, 1,   p‑PERK↝, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 3,   MGMT↓, 1,   P53↑, 2,   cl‑PARP↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 2,   P21↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   AXIN1↑, 1,   BMI1↓, 1,   CD44↓, 2,   CSCs↓, 2,   EMT↓, 13,   ERK↓, 3,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 2,   IGFBP3↑, 1,   Let-7↑, 3,   mTOR↓, 2,   mTOR↑, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   PTEN↑, 1,   Shh↓, 1,   STAT3↓, 6,   TCF↓, 2,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 7,   Wnt↓, 2,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

5LO↓, 1,   CA↓, 1,   Ca+2↑, 1,   E-cadherin↑, 15,   FAK↓, 2,   ITGB1↓, 1,   ITGB3↓, 1,   LEF1↓, 1,   MALAT1↓, 1,   MET↑, 1,   miR-139-5p↑, 1,   miR-200b↑, 1,   miR-200c↑, 1,   miR-203↑, 1,   MMP2↓, 3,   MMP7↓, 1,   MMP9↓, 5,   MMPs↓, 1,   N-cadherin↓, 5,   PDGF↓, 1,   Slug↓, 3,   p‑SMAD2↓, 1,   Snail↓, 9,   TGF-β↓, 3,   TumCI?, 1,   TumCI↓, 4,   TumCMig↓, 9,   TumCP↓, 4,   TumMeta↓, 4,   Twist↓, 1,   uPA↓, 1,   Vim↓, 19,   Zeb1↓, 4,   ZEB2↓, 1,   ZEB2↑, 1,   β-catenin/ZEB1↓, 7,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   p‑ATF4↝, 1,   EGFR↓, 1,   Hif1a↓, 7,   miR-210↓, 1,   VEGF↓, 7,  

Barriers & Transport ⓘ

CTR1↑, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CXCR4↓, 2,   IL1↓, 1,   IL6↓, 2,   Inflam↓, 1,   NF-kB↓, 7,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   ChemoSen↑, 3,   ChemoSen⇅, 1,   Dose↝, 1,   eff↓, 1,   eff↑, 3,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   IL6↓, 2,   PD-L1↓, 1,   PSA↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 1,   hepatoP↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 179

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   ROS↓, 2,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 2,  

Cell Death ⓘ

p‑Akt↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   PI3K↓, 1,  

Migration ⓘ

Ca+2↝, 1,   cal2↓, 1,   E-cadherin↑, 3,   F-actin↓, 1,   N-cadherin↓, 1,   Smad7↑, 1,   Snail↓, 1,   TIMP1↓, 1,   TumCMig↓, 1,   Vim↓, 3,   ZO-1↑, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   Inflam↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,  

Functional Outcomes ⓘ

memory↑, 1,   neuroP↑, 1,  
Total Targets: 25

Scientific Paper Hit Count for: Vim, Vimentin
2 Alpha-Lipoic-Acid
2 EGCG (Epigallocatechin Gallate)
2 Garcinol
2 Luteolin
2 Quercetin
1 2-DeoxyGlucose
1 Astragalus
1 Baicalin
1 Betulinic acid
1 Boswellia (frankincense)
1 Butyrate
1 Cannabidiol
1 Cisplatin
1 Paclitaxel
1 Honokiol
1 Metformin
1 Resveratrol
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:336  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page